Albireo. Slowly Taking Part of the Liver Disease Market (NASDAQ: ALBO)

don’t hurt

I have covered Albireo Pharma (NASDAQ: ALBO:) about four years ago. At the time, Albireo was a little-known liver disease company with a promising pipeline. Odevixibat, also known as A4250, was then undergoing a Phase 3 trial in PFIC, or Progressive Familial.

ALBO pipeline

ALBO pipeline (ALBIREO website)

About the TPT service

Thanks for reading. At Total Pharma Tracker we offer the following:

Our Android app and website contain a variety of tools for DIY investors, including current software where you can enter any indicator and receive extensive research material.

For investors who require hands-on support, our in-house experts go through our tools and find the best investable stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out what we can do for you at no cost.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top